Inhibitory effects of subcutaneous dexamethasone treatment on rat pulmonary toxicity of KW-2149, a new mitomycin C analogue

An experimental model for pulmonary toxicity of KW-2149, a new mitomycin C analogue, was established and the inhibitory effects of dexamethasone (DM) were investigated. KW-2149 was given to male rats 3 or 5 times at weekly intervals by intravenous injection of 3.28 or 8.2 mg/kg. As a suitable model...

Full description

Saved in:
Bibliographic Details
Published in:Archives of toxicology 2000-04, Vol.74 (2), p.106-111
Main Authors: TAKABA, K, FURUMOTO, H, IKEGAMI, J, SUZUKI, K, TAKAHASHI, J, HARA, T, ISHII, A
Format: Article
Language:English
Subjects:
Animals
Antibiotics, Antineoplastic - toxicity
Basement Membrane - drug effects
Basement Membrane - ultrastructure
Biological and medical sciences
Body Weight - drug effects
Clinical Chemistry Tests
Dexamethasone - therapeutic use
Disease Models, Animal
Drug Interactions
Drug toxicity and drugs side effects treatment
Dyspnea - chemically induced
Dyspnea - drug therapy
Endothelium - drug effects
Endothelium - ultrastructure
Glucocorticoids - therapeutic use
Hematologic Tests
Injections, Subcutaneous
KW-2149
Lung - drug effects
Lung - pathology
Male
Medical sciences
mitomycin C
Mitomycins - toxicity
Organ Size - drug effects
Pharmacology. Drug treatments
Pleural Effusion - chemically induced
Pleural Effusion - prevention & control
Rats
Rats, Sprague-Dawley
Toxicity: respiratory system, ent, stomatology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An experimental model for pulmonary toxicity of KW-2149, a new mitomycin C analogue, was established and the inhibitory effects of dexamethasone (DM) were investigated. KW-2149 was given to male rats 3 or 5 times at weekly intervals by intravenous injection of 3.28 or 8.2 mg/kg. As a suitable model for pulmonary toxicity, the dose of 3.28 mg/kg per week for 3 weeks was selected, this causing exudative pleural effusion in all animals but no deaths. For preventing this toxicity, DM was injected subcutaneously 3 times every week at 0.5, 1.0, 2.5 or 5.0 mg/kg. The 0.5 mg/kg dose was sufficient to completely prevent development of pleural effusions. Combined DM treatment may be an effective chemotherapy for KW-2149 induced pulmonary toxicity.
ISSN:0340-5761
1432-0738
DOI:10.1007/s002040050660